Frederick Barrett
Senior Research Scientist
Data updated
Research Footprint
Frederick Barrett appears in 43 tracked papers (2015–2026), most studied alongside Psilocybin, LSD and Mescaline, across Depressive Disorders, Anxiety Disorders and Healthy Volunteers.
Most-cited paper: Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder (1236 citations).
Frequent co-authors: Roland Griffiths, Matthew Johnson and Nathan Sepeda.
Publication Landscape
How the 43 papers Blossom tracks for Frederick Barrett line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Frederick Barrett's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 43 of 43 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Frederick Barrett publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Frederick Barrett publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Frederick S. Barrett is a psychologist and neuroscientist broadly affiliated with the field of clinical psychedelic research, best known for collaborative work with major centres in the United States on psilocybin and other serotonergic compounds. He has played a prominent role in trials and human laboratory studies exploring therapeutic applications of psychedelics, as well as mechanistic investigations using neuroimaging and receptor-occupancy approaches. Barrett is a frequent co-author with investigators such as Roland R. Griffiths and Matthew W. Johnson and has contributed to both clinical trial reports and methodological papers that seek to strengthen rigour in psychedelic research.
Barrett's substantive contributions include the development and validation of psychometric instruments used to quantify acute subjective phenomena (for example, measures of challenging experiences and psychological insight), analyses of safety signals (including work examining coadministration risks such as seizures associated with lithium), and experimental studies of music-evoked brain activity under LSD and psilocybin. He has also contributed to naturalistic cohort studies and to comparative cognition research examining hallucinogen users versus controls. Across these domains he has emphasised careful measurement, reproducible methods, and the integration of subjective-report instruments with neurobiological data to advance understanding of therapeutic mechanisms and safety considerations in psychedelic-assisted interventions.
Key Impact
Frederick S. Barrett is a leading researcher in contemporary psychedelic science noted for developing psychometric tools, characterising challenging and insightful psychedelic experiences, and contributing to neuroimaging and safety research on psilocybin and other classic psychedelics.
Collaboration Network
72 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Frederick Barrett's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Frederick Barrett is associated with.
Johns Hopkins University
academicThe Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
View stakeholder →Johns Hopkins Center for Psychedelic and Consciousness Research
The Johns Hopkins Center for Psychedelic and Consciousness Research sits within the School of Medicine in Baltimore and is one of the most established programmes of its kind. It opened in 2019 with roughly 17 million dollars in private donations, and was founded under Roland Griffiths, whose earlier psilocybin work helped revive modern clinical study of these compounds. Frederick Barrett took over as director in 2023. The centre studies how classic psychedelics such as psilocybin affect brain function, cognition and mood, and runs trials in conditions including depression, tobacco dependence and anorexia. Its scientists combine clinical trials with neuroimaging and questionnaire measures of the psychedelic experience, and much of the field's shared vocabulary traces back to work done here.
View stakeholder →